Compare HTOO & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTOO | LYRA |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.6M |
| IPO Year | N/A | 2020 |
| Metric | HTOO | LYRA |
|---|---|---|
| Price | $4.55 | $1.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 131.5K | 102.7K |
| Earning Date | 02-28-2023 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,024,662.00 | $600,000.00 |
| Revenue This Year | $4,832.46 | N/A |
| Revenue Next Year | $81.82 | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 105.98 | N/A |
| 52 Week Low | $2.92 | $1.63 |
| 52 Week High | $19.37 | $37.50 |
| Indicator | HTOO | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.80 | 27.52 |
| Support Level | $4.08 | $1.63 |
| Resistance Level | $3.81 | $3.94 |
| Average True Range (ATR) | 0.37 | 0.25 |
| MACD | 0.12 | -0.14 |
| Stochastic Oscillator | 73.86 | 15.37 |
Fusion Fuel Green PLC is a provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. It offers a broad portfolio of services, including the design, supply, installation, and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors. The group currently derives revenue by providing comprehensive solutions for the liquefied petroleum gas (LPG) industry, which includes the supply, installation, and maintenance of LPG systems, as well as transportation and delivery of LPG in both bulk and cylinder formats.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.